Kurma Partners

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.